BIODESIX INC BDSX
Biodesix, Inc. ("Biodesix", "we," "us," "our" or the "Company") is a leading diagnostic solutions company. Our mission at Biodesix is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible, and address immediate clinical needs. We envision a world where patient disease is conquered through the guidance of personalized diagnostics.
We derive our revenue from two sources: (i) Biodesix Lung Diagnostic Testing (Lung Diagnostic Testing), providing lung diagnostic testing services for healthcare providers associated with our five blood-based tests and (ii) Biodesix Development Services (Development Services) providing diagnostic testing services and consulting to biopharmaceutical, life sciences, and diagnostic companies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $88.5M | $71.3M | $49.1M | $38.2M | $54.5M | $45.6M | $24.6M | — |
| R&D | $12.0M | $9.6M | $10.0M | $13.1M | $12.8M | $10.8M | $10.5M | — |
| SG&A | $87.5M | $80.5M | $67.4M | $61.5M | $50.5M | $34.9M | $30.6M | — |
| Total operating expenses | $116.4M | $105.8M | $90.4M | $88.8M | $95.4M | $68.5M | $51.3M | — |
| Operating income | -$27.9M | -$34.5M | -$41.3M | -$50.6M | -$40.9M | -$22.9M | -$26.7M | — |
| Interest expense | $7.7M | $8.3M | $9.5M | $8.1M | $4.5M | $7.6M | $3.0M | — |
| Pre-tax income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | -$43.2M | -$65.4M | — | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$35.3M | -$42.9M | -$52.1M | -$65.4M | -$43.2M | -$65.4M | -$30.7M | — |
| EPS, basic | -4.67 | -6.64 | -0.64 | -1.55 | -1.58 | — | — | — |
| EPS, diluted | -4.67 | -6.64 | -0.64 | -1.55 | -1.58 | -6.48 | -126.97 | — |
| Shares, diluted (wtd. avg.) | 7.6M | 6.5M | 82.1M | 42.1M | 27.4M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $19.0M | $26.2M | $26.4M | $43.2M | $32.8M | $62.3M | $5.5M | $6.1M |
| Receivables | $9.0M | $8.6M | $7.7M | $5.1M | $3.7M | $15.3M | $5.3M | — |
| Total current assets | $32.5M | $39.5M | $39.7M | $53.3M | $43.6M | $86.1M | $12.7M | — |
| Property, plant and equipment | $24.8M | $27.8M | $27.9M | $5.8M | $4.2M | $3.2M | $2.1M | — |
| Goodwill | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M | $15.0M | $14.2M |
| Other intangibles | $3.9M | $5.9M | $7.9M | $9.8M | $11.6M | $13.3M | $15.1M | — |
| Total assets | $87.5M | $97.2M | $99.1M | $92.9M | $76.1M | $121.1M | $45.0M | — |
| Accounts payable | $3.1M | $2.2M | $2.9M | $1.7M | $1.7M | $9.0M | $1.7M | — |
| Total current liabilities | $17.4M | $14.3M | $33.4M | $22.8M | $29.0M | $32.1M | $22.6M | — |
| Long-term debt | $50.0M | $40.0M | $40.1M | $30.1M | $10.1M | $28.1M | — | — |
| Total liabilities | $89.9M | $76.4M | $94.5M | $72.3M | $56.4M | $79.9M | $76.2M | — |
| Retained earnings | -$497.8M | -$462.5M | -$419.6M | -$367.4M | -$302.0M | -$258.8M | -$227.5M | — |
| Total equity | -$2.5M | $20.9M | $4.6M | $20.6M | $19.7M | $41.2M | -$225.1M | -$194.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.3M | -$48.6M | -$22.9M | -$45.0M | -$28.2M | -$21.4M | -$21.7M | — |
| Stock-based compensation | $4.1M | $6.6M | $5.4M | $6.0M | $4.9M | $3.7M | $170.0K | — |
| Capital expenditure | $259.0K | $3.2M | $22.9M | $3.3M | $2.2M | $1.9M | $1.3M | — |
| Investing cash flow | -$403.0K | -$3.4M | -$23.1M | -$3.5M | -$2.5M | -$2.9M | -$1.9M | — |
| Financing cash flow | $16.4M | $52.0M | $29.1M | $58.9M | $1.3M | $81.1M | $23.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-149633.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $24.6M | $45.6M | $54.5M | $38.2M | $49.1M | $71.3M | $88.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$30.7M | -$65.4M | -$43.2M | -$65.4M | -$52.1M | -$42.9M | -$35.3M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event Item 8.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |